Double blind clinical trial comparing the safety and efficacy of nimesulide (100mg) and diclofenac in osteoarthrosis of the hip and knee joints

West African Journal of Medicine

Volumn 24, Issue 2, 2005, Pages 128-133

  Omololu, Bade ^a   Alonge, T O ^a   Ogunlade, S O ^a   Aduroja, O O ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Diclofenac; Hip; Knee; Nimesulide; Osteoarthritis

Indexed keywords

DICLOFENAC; NIMESULIDE; NIMULID; PARACETAMOL;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HEARTBURN; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOMES RESEARCH; OUTPATIENT CARE; PAIN ASSESSMENT; PATIENT REFERRAL; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 23044432618     PISSN: 0189160X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Nimesulide in the treatment of osteoarthritis - Double blind studies in comparison with piroxicam, ketopprofen and placebo. Drugs 1993; 46 (suppl. 1) 191-195.
2. Jackson CG, Therapeutic potential of Cox-2 inhibitors in arthritis. Expert Opin Investig. Drugs 2001 10 1317-1325.
3. Fusetti G., et al. Tolerability of Nimesulide - Epidemiological data. Drugs 1993; 46 (suppl. 1) 277-280.
4. Pelletier JP and Pelletier JM. Effects of Nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs: 1993;46 (Suppl. 1) 34-39.
5. Fuj-Y, Masferrer JL, Seibert K et al-The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol. Chem 1990, 265;1637-40.
6. Alan Ward and Rex Grogden. Nimesulide - A Preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain state. Drugs 1988; 36: 732-753.
7. Masferrer JL, Zweifel BS, Seibert K, Needleman P; Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin. Invest. 1990;86,1375-9.
8. Mitchell JA, Akaraseveenont P, Thiemermann C et al; Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl.Acad. Sci USA 1994; 90; 11693-7
9. Antiplatelet Trialist Collaboration. Collaborative overview of randomized trials of antiplatelet therapy In Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med. J 1994, 308; 81-106
10. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G. Hsynthase:c DNA cloning. expression and gene chromosomal assignment. FASEB J 1991; 5: 2304-12.
11. Vane JR, Botting RM; A better understanding of anti inflammatory drugs based on isoforms of cyclooxygenase cox-1 and cox-2 In: Advances in prostaglandin, thromboxane and leukotriene research vol. 23 edited by B. Samuelsson et al Raven Press Ltd. New York1995.pg340-347.
12. Appel GB, Cox-2 inhibitors and the kidney. Clin Exp. Rheumatol. 2001 196 Supp 25 -S 37-40.